8-K/A filing — Atrium Therapeutics, Inc. (RNA)
Filed: 2026-10-09 AccNo: 0001193125-26-418417 Size: 146 KB Item 8.01: Other Events
Stocks · News reference
Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate
Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.01) by 16.83 percent. This is a 2.48 percent increase over losses of $(1.21) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Atrium Therapeutics, Inc. (RNA)
Filed: 2026-10-08 AccNo: 0001193125-26-417402 Size: 685 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Atrium Therapeutics Announces $50M Private Placement Of 5,170,384 Shares And Pre-Funded Warrants To Purchase Up To 1,134,930 Shares At ~$7.93/Unit
Company entered into a securities purchase agreement (the "purchase agreement") with a group of leading institutional investors for a private placement financing (the "private placement"). The private
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Atrium Therapeutics (NASDAQ:RNA) with a Buy and maintains $25 price target.